33 studies found for:    " September 22, 2010":" October 22, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" September 22, 2010":" October 22, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Longitudinal Study of Dental Implant Therapy in HIV- Positive Patients
Condition: HIV Positive Patient Receive Implant Supported Restoration
Intervention:
2 Active, not recruiting Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
Conditions: Drug Interactions;   Human Immunodeficiency Virus
Intervention: Drug: Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
3 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Efavirenz 600 mg once daily
4 Recruiting Chinese Network of Pediatric Antiretroviral Therapy
Condition: Acquired Immunodeficiency Syndrome
Intervention:
5 Active, not recruiting A Study to Assess the Efficacy of Raltegravir, Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
Condition: HIV-1 Infection
Intervention: Drug: Raltegravir
6 Recruiting Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients
Conditions: Human Immunodeficiency Virus;   Disorder of Immune Reconstitution
Interventions: Drug: high dose of MSC;   Drug: low dose of MSC treatment
7 Active, not recruiting
Has Results
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572 (dolutegravir);   Drug: raltegravir;   Other: GSK1349572 Placebo;   Other: ABC/3TC;   Other: TDF/FTC;   Other: raltegravir Placebo
8 Completed HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Conditions: Chronic HIV Infection;   HCV Coinfection
Intervention: Drug: Fosamprenavir
9 Recruiting Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Conditions: Anal Cancer;   Nonneoplastic Condition;   Penile Cancer;   Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;   Other: laboratory biomarker analysis
10 Active, not recruiting Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Condition: HIV
Intervention: Drug: Tenofovir/emtricitabine and raltegravir
11 Completed
Has Results
Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
Condition: HIV Infection
Intervention: Drug: Azithromycin
12 Completed Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad35-ENV vaccine;   Biological: Ad26.ENVA.01 vaccine;   Biological: Placebo Control
13 Recruiting Study to Improve Survival Among HIV-Exposed Infants in Botswana
Conditions: HIV Infections;   Neutropenia;   Anemia
Interventions: Drug: cotrimoxazole prophylaxis;   Drug: cotrimoxazole placebo;   Behavioral: exclusive breastfeeding until 6 months of age;   Behavioral: breastfeeding for 12 months
14 Completed Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants
Condition: HIV Infections
Intervention:
15 Active, not recruiting Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
Conditions: HIV Infections;   Heart Disease
Interventions: Drug: Rosuvastatin 10 mg. daily for 96 weeks;   Drug: Placebo
16 Unknown  Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.
Conditions: 1- Women;   2- HIV Infection;   3- Followed in West Indies and French Guiana for His Infection;   4- Acceptance of the Use of Nadis® Medical Files
Intervention: Other: Biological Sample collection
17 Active, not recruiting
Has Results
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1349572;   Drug: Raltegravir;   Drug: GSK1349572 Placebo;   Drug: Raltegravir Placebo
18 Completed GSK1349572 Hepatic Impairment Study
Conditions: Healthy Subjects;   Hepatic Impairment;   Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK1349572
19 Completed A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
Condition: Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions: Drug: GSK1349572;   Drug: Placebo;   Drug: Iohexol Injection;   Drug: Para-aminohippurate infusion
20 Completed Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires
Conditions: Malaria;   Schistosomiasis;   Hiv Infection
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results
Indicates status has not been verified in more than two years